Cellectis presents CAR-T therapy results at EHA 2026

NEWS – June 11, 2026 – Cellectis, a clinical-stage biotechnology company developing cell and gene therapies, today presented final Phase 1 data from the BALLI-01 trial of lasme-cel and preliminary data from the NATHALI-01 study of eti-cel at the European Hematology Association (EHA) 2026 Congress.

The BALLI-01 study evaluated lasme-cel, a CD22-directed allogeneic CAR-T therapy, in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Final Phase 1 data for lasme-cel showed a 100% overall response rate (ORR) in the target Phase 2 population (7/7 patients), with 57% achieving complete remission or complete remission with incomplete count recovery (CR/CRi). Patients in this group were heavily pretreated, often having received multiple prior therapies, including CAR-T treatments.

The safety profile of lasme-cel was deemed manageable, with Grade 3 cytokine release syndrome (CRS) occurring in 4% of patients and Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS) in 4%. All reported severe adverse events resolved.

The NATHALI-01 study investigated eti-cel, a CAR-T therapy targeting both CD20 and CD22, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). This patient population had a median of 3 prior lines of therapy, and 93% had previously received CD19-directed CAR-T therapy. In the optimal dose cohort, an ORR of 88% and a complete response rate of 63% were observed.

Analysis indicated a positive correlation between alemtuzumab exposure and clinical outcomes, suggesting that optimizing lymphodepletion may enhance CAR-T expansion and treatment response. These presentations at EHA 2026 highlight the ongoing development of Cellectis' cell therapies for challenging hematologic malignancies.